secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0000950170-23-058240
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx Q3 revenue $98.1M (+8% YoY); reaffirms FY2023 guidance $425-450M
---------------------------------------------------------------------------

- Total revenue $98.1M, up 8% YoY; Crysvita $74.9M, Dojolvi $16.6M.
- Net loss $159.6M ($2.23/share), improved from $245.1M ($3.50/share) in Q3 2022.
- Cash $524.2M at Sept 30; net $326.5M from October offering.
- FY2023 guidance reaffirmed: total revenue $425-450M, Crysvita $325-340M, Dojolvi $65-75M.
- Clinical: UX143 (OI) 67% fracture rate reduction; GTX-102 (Angelman) improvements; UX701 (Wilson) patients tapering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023058240/0000950170-23-058240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023058240/rare-20231102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-058240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer